%0 Journal Article
%A Mathew, A.
%A Capdevila, J.
%A Unger, N.
%A Fendler, W.
%A Theurer, S.
%A Weber, F.
%A Fuhrer, D.
%A Lahner, H.
%T Lenvatinib as Salvage Therapy in Advanced and Progressive GI-NET.
%J Endocrine related cancer
%V 32
%N 8
%@ 1351-0088
%C Bristol
%I Soc. for Endocrinology
%M DKFZ-2025-01620
%P e250165
%D 2025
%Z 2025 Aug 20;32(8):e250165
%X The efficacy of lenvatinib in treating gastrointestinal neuroendocrine tumors (GI-NET) has been explored in preclinical studies and early-phase clinical trials but real-world data remains limited. Data of sixteen patients (median age 65 years; 62.5
%K NET (Other)
%K TKI (Other)
%K lenvatinib (Other)
%K neuroendocrine tumors (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40748172
%R 10.1530/ERC-25-0165
%U https://inrepo02.dkfz.de/record/303371